TECH · Full Picture

BIO-TECHNE Corp — the full picture

Trailing window · 2026-05-11 to 2026-08-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 56
    1 forward row(s); quote_verified
    Amundi reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 67.2% during the first quarter, selling 148,342 shares and retaining 72,315 shares valued at approximately $3.8 million.
  2. Market Demand Trends · Demand, orders & backlogPriority 27
    quote_verified
    The Research Use (RUO) Recombinant Protein Market is projected to grow from USD 1.11 billion in 2026 to USD 1.55 billion by 2031, at a CAGR of 7.0%.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 25
    quote_verified
    Bio-Techne's revenue was down 1.5% year-over-year to $311.42 million in Q1.

Threads by pillar

Revenue & Demand Priority 30 · 2 threads

Strategy & Portfolio Priority 56 · 1 thread